a*e
2 楼
涨了
N*p
5 楼
February 25th is the day that Vivus (VVUS) will offer its Q4 quarterly
conference call. There will be a lot of ears listening to the call, but many
of them will not even have an investment in Vivus. Others that will be
paying close attention are investors in Arena (ARNA) and Orexigen (OREX).
Vivus, Arena and Orexigen all are vying for a position in the prescription
anti-obesity market, and while the three companies are at different stages,
the results offered by Vivus could be telling in what to expect moving
forward.
http://seekingalpha.com/article/1215041-vivus-arena-and-orexige
【在 a*********e 的大作中提到】![](/moin_static193/solenoid/img/up.png)
: 纯TA.
conference call. There will be a lot of ears listening to the call, but many
of them will not even have an investment in Vivus. Others that will be
paying close attention are investors in Arena (ARNA) and Orexigen (OREX).
Vivus, Arena and Orexigen all are vying for a position in the prescription
anti-obesity market, and while the three companies are at different stages,
the results offered by Vivus could be telling in what to expect moving
forward.
http://seekingalpha.com/article/1215041-vivus-arena-and-orexige
【在 a*********e 的大作中提到】
![](/moin_static193/solenoid/img/up.png)
: 纯TA.
b*p
6 楼
这篇文章有意思!很受启发,谢谢!
many
,
【在 N**********p 的大作中提到】![](/moin_static193/solenoid/img/up.png)
: February 25th is the day that Vivus (VVUS) will offer its Q4 quarterly
: conference call. There will be a lot of ears listening to the call, but many
: of them will not even have an investment in Vivus. Others that will be
: paying close attention are investors in Arena (ARNA) and Orexigen (OREX).
: Vivus, Arena and Orexigen all are vying for a position in the prescription
: anti-obesity market, and while the three companies are at different stages,
: the results offered by Vivus could be telling in what to expect moving
: forward.
: http://seekingalpha.com/article/1215041-vivus-arena-and-orexige
many
,
【在 N**********p 的大作中提到】
![](/moin_static193/solenoid/img/up.png)
: February 25th is the day that Vivus (VVUS) will offer its Q4 quarterly
: conference call. There will be a lot of ears listening to the call, but many
: of them will not even have an investment in Vivus. Others that will be
: paying close attention are investors in Arena (ARNA) and Orexigen (OREX).
: Vivus, Arena and Orexigen all are vying for a position in the prescription
: anti-obesity market, and while the three companies are at different stages,
: the results offered by Vivus could be telling in what to expect moving
: forward.
: http://seekingalpha.com/article/1215041-vivus-arena-and-orexige
a*e
9 楼
接着涨。
t*s
11 楼
不有效突破9,就洗洗睡吧
相关阅读